People
With the adaptation of new technologies, tech executives are finding new homes in biotech and the life sciences.
Lilly’s most recent legal woes come from a proposed class-action lawsuit filed on Wednesday, accusing the company of age bias.
The life sciences industry was well-represented, with a handful of names featured in the top 100.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Between April 2020 and today, the executive board of Kyowa Kiran North America (KKNA) has grown from being predominantly male to a 50/50 gender split.
Multiple reports suggest an exodus of BIO team members over price control issues. BIO reorganized its leadership structure to provide what was expected to be “long-term stability for the organization.”
Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.
This is an effort to eliminate severe adverse reactions by matching the birth control to the genetics and hormones of the individual.
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
Teva announced the appointment in a filing with the U.S. Securities and Exchange Commission. Zaks will serve on the board’s Science and Technology Committee.
PRESS RELEASES